设为首页 | 加入收藏
文献检索:
  • On the Road to Conquering Cancer with You: Notes on the New Look of Our Publication--Editorial Board of Oncology and Translational Medicine 免费阅读 下载全文
  • Progress in lung cancer treatment 免费阅读 下载全文
  • Advancements in radiotherapy for lung cancer in China 免费阅读 下载全文
  • Lung cancer is the leading cause of death due to cancer in China. In recent years, great progress has been made in radiotherapy for lung cancer patients in China. The main advancements include the following aspects:(1) stereotactic ablative radiotherapy for early stage nonsmall cell lung cancer(NSCLC),(2) post-operative radiotherapy for NSCLC,(3) combined chemotherapy and radiotherapy for locally advanced NSCLC,(4) improved radiotherapy for advanced NSCLC, and 5) prediction of radiation-induced lung toxicity.
  • Anti-angiogenesis therapy for lung cancer: the shore and the other shore 免费阅读 下载全文
  • Angiogenesis is known to be an important event in tumor growth. In preclinical and clinical researches, anti-angiogenesis therapy has made great progress, but there are still many problems for future anti-angiogenesis therapy. Here, we review recently completed clinical trials of emerging antiangiogenic agents in patients with non-small cell lung cancer(NSCLC) and discuss the challenges of anti-angiogenic therapy.
  • Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer 免费阅读 下载全文
  • Drugs that specifically target the tyrosine kinase domain of epidermal growth factor receptor(EGFR), such as erlotinib or gefitinib, have exhibited striking efficacy in non-small cell lung cancer(NSCLC) patients harboring activating EGFR mutations. However, acquired resistance inevitably develops and remains a serious barrier for the successful management of patients with this disease. Multiple mechanisms are reportedly involved in the process of acquired resistance, which provide new insights into the management of EGFRtyrosine kinase inhibitor(EGFR-TKI) resistance. Here, we provide an overview of the emerging treatment approaches for patients with EGFR-TKI resistance.
  • Efficacy analysis and multi-factor retrospective study of third-line chemotherapy in 82 Chinese patients with small cell lung cancer 免费阅读 下载全文
  • Objective As there is currently no clear recommendation for third-line chemotherapy for small cell lung cancer(SCLC), its efficacy is unknown. To date, there have rarely been reports of Chinese patients with SCLC who received third-line chemotherapy. Therefore, we investigated the efficacy, safety, and prognostic factors of Chinese patients with SCLC treated with third-line chemotherapy.Methods A retrospective analysis of patients with SCLC who received third-line chemotherapy was performed.Results Between 2007 and 2013, 82 patients [62 men(75.6%), 20 women(24.4%); median age at the time of diagnosis, 55 years] received third-line chemotherapy at our center. Of these patients, 44 had limited-stage disease and 38 had extensive-stage disease. On third-line chemotherapy, 55(67.1%) patients had an Eastern Cooperative Oncology Group performance status(ECOG PS) of 0–1, objective response rate of 15.9%, and median overall survival after third-line chemotherapy(OS-3) and median progression-free survival after third-line chemotherapy(PFS-3) of 5.6 months and 3.0 months, respectively. On univariate analysis, PFS-3 was significantly related with ECOG PS(P = 0.005), response to second-line chemotherapy(P = 0.002), response to third-line chemotherapy(P < 0.001), and PFS after second-line chemotherapy(P = 0.026). OS-3 was significantly related with ECOG PS(P < 0.001), response to thirdline chemotherapy(P = 0.033), PFS after first-line therapy(P = 0.044), and PFS after second-line therapy(PFS-2)(P = 0.007). On multivariate analysis, ECOG PS(P = 0.008) and response to third-line chemotherapy(P = 0.046) were independent prognostic factors for PFS-3, while ECOG PS(P = 0.007) and PFS-2(P < 0.001) were independent prognostic factors for OS-3.Conclusion Few patients with SCLC receive third-line chemotherapy. Our findings suggest that patients with an ECOG PS 0–1 and PFS-2 for >3 months will be benefit from third-line chemotherapy, which should be actively offered to them.
  • Chinese experts' consensus on diagnosis, prevention, and treatment of chemotherapy-induced hepatotoxicity 免费阅读 下载全文
  • <正>Overview Drug-induced liver injury(DILI)due to acetaminophen overdose and idiosyncratic drug reactions usually occurs 5–90 days after exposure to the causative drug.Ninety percent of DILI cases are acute.As one of the most common non-infectious liver diseases,DILI represents a growing challenge for clinicians.According to data from WHO[1],DILI is the fifth leading cause of liver disease mortality.In China,DILI accounts for 1%–5%of hospitalized patients with liver diseases,10%of patients with
  • Effect of dendritic cell/cytokine-induced killer cell immunobiological cancer therapy combined with adjuvant chemotherapy in patients with triple-negative breast cancer 免费阅读 下载全文
  • Objective The aim of the present study was to investigate the effect of dendritic cell(DC)/cytokine-induced killer cell(CIK) immunobiological cancer therapy in patients with triple-negative breast cancer(TNBC) who underwent adjuvant chemotherapy. Methods From January 2010 to October 2013, 120 patients with postoperative TNBC were recruited and included in the study. Patients were enrolled in one of two groups according to whether they accepted DC/CIK immunobiological cancer therapy during adjuvant chemotherapy; the patients in the DC/CIK group underwent adjuvant chemotherapy combined with DC/CIK immunobiological cancer therapy, and the control group underwent adjuvant chemotherapy alone. When six cycles of adjuvant chemotherapy and six cycles of DC/CIK immunobiological cancer therapy had been completed, differences between the two groups with regard to quality of life(Qo L), immunological indicators(CD3, CD4, CD8, and NK cell levels), disease-free survival(DFS), and side effects of chemotherapy and DC/CIK treatment were evaluated.Results In the DC/CIK group, the proportion of NK cells and CD3+ and CD4+ T-cell subgroups significantly increased, and the proportion of CD8+ cells decreased when they were compared before and after DC/CIK therapy(P < 0.05). However, there were no significant changes in the control group. By the final follow-up, DFS of the treatment group and the control group was 38.4 and 34.2 months, respectively. The Qo L improved in the patients treated with chemotherapy plus DC/CIK therapy compared with the patients treated with chemotherapy alone, and the difference between groups was significant(P < 0.05). The side effects of two groups were tolerable and not significantly different between the two groups.Conclusion The DC/CIK treatment had potential benefits for patients with TNBC compared with the control group, and was not associated with any obvious side effects. Therefore, DC/CIK therapy is a safe and effective method for the treatment of TN...
  • Expression of Bmi-1 and EZH2 in tissues adjacent to human epithelial ovarian cancer cells of orthotopic implantation in nude mice 免费阅读 下载全文
  • Objective This study investigated the feasibility of screening residual normal ovarian tissues based on the expression of Bmi-1 and EZH2 in tissues adjacent to orthotopic ovarian carcinomas in nude mice. Methods The human epithelial ovarian cancer cell line OVCAR3 was grown in subcutaneous tissues and the tumor tissues were orthotopically implanted. The expression levels of Bmi-1 and EZH2 were detected by immunohistochemical staining and RT-PCR in cancer tissues, proximal and remote tissues with respect to the cancer tissues, and normal ovarian tissues of nude mice.Results Thirty-five ovarian tissue samples with normal biopsy results were obtained from 40 cases of human epithelial ovarian cancer in the nude mice in which the tumor tissues were orthotopically implanted. Bmi-1 and EZH2 expression levels were lower in proximal paraneoplastic tissue samples than in cancer tissue samples(P < 0.05) and higher than in remote paraneoplastic tissue samples(P < 0.01). No significant difference was found in the expression levels of Bmi-1 and EZH2 using immunohistochemistry among residual normal ovarian tissues obtained from orthotopically implanted models that differed in severity. The expression of Bmi-1 and EZH2 was negative in 20 normal ovarian tissue samples.Conclusion The expression levels of Bmi-1 and EZH2 were reduced with increasing distance from the cancer tissues. Negative expression of these tumor-associated genes can be used as a standard for the screening of normal ovarian tissues adjacent to tumor tissues. Normal ovarian tissues can be obtained from the tissues adjacent to tumors.
  • 《中德临床肿瘤学杂志:英文版》封面
      2015年
    • 01
    • 02

    主管单位:教育部

    主办单位:华中科技大学

    主  编:陈安民

    地  址:武汉解放大道1095号 同济医院内

    邮政编码:430030

    电  话:027-83662630

    电子邮件:dmedizin@tjh.tjmu.edu.cn

    国际标准刊号:issn 1610-1979

    国内统一刊号:cn 42-1654/r

    邮发代号:38-121

    单  价:28.00

    定  价:336.00


    关于我们 | 网站声明 | 合作伙伴 | 联系方式 | IP查询
    金月芽期刊网 2017 触屏版 电脑版 京ICP备13008804号-2